Peder Andersen
Chief Tech/Sci/R&D Officer chez BIOSERGEN AB
Profil
Peder Møller Andersen is currently the Chief Executive Officer & Director at Biosergen.
AS since 2017.
He is also the Chief Medical Officer at Biosergen AB.
Previously, he worked as the Managing Director at Forward Pharma GmbH from 2009 to 2016.
He also served as the Vice President-Clinical Development at Astion Pharma.
A from 2010 to 2012.
Additionally, he was the Chief Operating Officer at Forward Pharma A in 2017.
Dr. Andersen obtained his doctorate degree from the University of Copenhagen in 1981.
Postes actifs de Peder Andersen
| Sociétés | Poste | Début |
|---|---|---|
| BIOSERGEN AB | Chief Tech/Sci/R&D Officer | 31/01/2024 |
Biosergen AS
 Biosergen AS BiotechnologyHealth Technology Biosergen AS develops drugs based on biosynthetic engineering of natural products, combined with chemical synthesis. It develops antibiotics for the use in antifungal therapy. The firm uses engineered biosynthesis technology that allows alterations in microbial genes, which lead to predictable changes in the final structure of the natural product. The company was founded in 2004 and is headquartered in Tiller, Norway. | Chief Executive Officer | 01/01/2017 |
Anciens postes connus de Peder Andersen
| Sociétés | Poste | Fin |
|---|---|---|
| FORWARD PHARMA A/S | Chief Executive Officer | 01/03/2017 |
Forward Pharma GmbH
 Forward Pharma GmbH Miscellaneous Commercial ServicesCommercial Services Part of Forward Pharma A/S, Forward Pharma GmbH is a German company that engages in researching and developing biotechnology. The company is based in Leipzig, Germany. | Chief Executive Officer | 01/01/2016 |
Astion Pharma A/S
 Astion Pharma A/S Pharmaceuticals: MajorHealth Technology Astion Pharma A/S develops and manufactures pharmaceutical products. It focuses on developing anti-inflammatory drugs for dermatological and immunological diseases. The company was founded by Morten S. Weidner in 1992 and is headquartered in Copenhagen, Denmark. | Chief Tech/Sci/R&D Officer | 01/01/2012 |
Formation de Peder Andersen
| University of Copenhagen | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| BIOSERGEN AB | Health Technology |
| Entreprise privées | 4 |
|---|---|
Astion Pharma A/S
Astion Pharma A/S Pharmaceuticals: MajorHealth Technology Astion Pharma A/S develops and manufactures pharmaceutical products. It focuses on developing anti-inflammatory drugs for dermatological and immunological diseases. The company was founded by Morten S. Weidner in 1992 and is headquartered in Copenhagen, Denmark. | Health Technology |
Forward Pharma A/S
 Forward Pharma A/S Pharmaceuticals: MajorHealth Technology Forward Pharma A/S is a biopharmaceutical company, which engages in the research and development of medicinal treatment for inflammatory and neurological indications. It focuses on the immunomodulatory compound dimethyl fumarate and its derivatives. The company was founded by Florian Schönharting on July 2005 and is headquartered in Copenhagen, Denmark. | Health Technology |
Biosergen AS
Biosergen AS BiotechnologyHealth Technology Biosergen AS develops drugs based on biosynthetic engineering of natural products, combined with chemical synthesis. It develops antibiotics for the use in antifungal therapy. The firm uses engineered biosynthesis technology that allows alterations in microbial genes, which lead to predictable changes in the final structure of the natural product. The company was founded in 2004 and is headquartered in Tiller, Norway. | Health Technology |
Forward Pharma GmbH
Forward Pharma GmbH Miscellaneous Commercial ServicesCommercial Services Part of Forward Pharma A/S, Forward Pharma GmbH is a German company that engages in researching and developing biotechnology. The company is based in Leipzig, Germany. | Commercial Services |
